LENZ Therapeutics, Inc.
Nasdaq: LENZBiological Products, (No Diagnostic Substances) · Entity-resolved by Clous
CIK0001815776
TickerLENZ
ExchangeNasdaq
SIC2836
StateDE
FY end12-31
Key financials
RevenueFY2025-12-31
$19.09M
—
Net IncomeFY2025-12-31
-$82.13M
-65.0% YoY
Total AssetsFY2025-12-31
$305.88M
+42.1% YoY
EquityFY2025-12-31
$284.34M
+39.3% YoY
Shares OutstandingFY2025-12-31
31.35M
—
Operating Cash FlowFY2025-12-31
-$69.17M
-16.5% YoY
Short interest & fails
Fails-to-deliver
SEC CNS fails · semi-monthly15.3K
shares failed · 2026-05-28
2026-05-2815.3K sh$7.73
2026-05-2715.37K sh$7.75
2026-05-2621.13K sh$7.55
2026-05-2110.12K sh$7.20
2026-05-196.41K sh$6.90
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $19.09M | — | 100% |
| Net Income | -$101.05M | -$124.65M | -$49.77M | -$82.13M | -65.0% | -430% |
| Total Assets | $321.9M | $188.46M | $215.3M | $305.88M | +42.1% | 1602% |
| Equity | $296.29M | $183.58M | $204.08M | $284.34M | +39.3% | 1490% |
| Operating Cash Flow | -$87.98M | -$90.01M | -$59.39M | -$69.17M | -16.5% | -362% |
| Shares Outstanding | — | — | — | 31.35M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001815776